ESR1 and cancer: For instance, Mamnoon et al. developed estradiol-conjugated hypoxia-responsive DDSs loaded with DOX for targeted drug delivery to hypoxic niches in estrogen receptor (ER)-positive breast cancer, being the first report of targeted ER-mediated hypoxia-responsive polymeric drug carriers for cancer treatment [198].